Mary Chamberlin, MD
Medical Oncology · Lebanon, NHNPI 1841302593
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $59 of the $70 with a category attached, or 83.1%. 3 manufacturers reported payments, led by Eli Lilly at 56.9% of the total. 2024 is the largest year on record at $40, 2.2 times the $18 reported in 2019. That places this record below the midpoint for medical oncology clinicians in NH, where the typical reported total is $368.
Across 3 payments — averaging $23.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$40
- Organogenesis Inc.$18
- Gilead$12
Across 164 payments — averaging $2276.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$264K
- Pfizer$72K
- Genentech, Inc.$34K
- Merck$3K
What the payments were for
- Food & beverage$5983%
- Education$1217%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 1 | $40 |
| Organogenesis Inc. | 1 | $18 |
| Gilead | 1 | $12 |
How this compares
$70 in reported general payments places this provider in the 20th percentile of 20 medical oncology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 30 | $430,827 |
| OrserduElacestrant Hcl | 18 | $407,863 |
| VerzenioAbemaciclib | 15 | $222,021 |
| Letrozole | 322 | $7,218 |
| Exemestane | 23 | $3,213 |
| Anastrozole | 88 | $2,289 |
| Tamoxifen Citrate | 23 | $847 |
| Alendronate Sodium | 36 | $373 |
| Prochlorperazine Maleate | 20 | $212 |
| Oxycodone Hcl | 14 | $206 |
| Dexamethasone | 11 | $173 |
| Ondansetron Hcl | 16 | $125 |
| Gabapentin | 23 | $72 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Lebanon
- Peter KaufmanLebanon$651K
- James RigasLebanon$251K
- Tyler CurielLebanon$29K
- Charles GaulinLebanon$20K
- Linda VahdatLebanon$20K
- Tara KaufmannLebanon$656
- Hilal HachemLebanon$368
- Jacob ReibelLebanon$87
- Gabriel BrooksLebanon$50
- Bradley ArrickLebanon$12
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.